1. Home
  2. Search

Search

Search results

374 results found

Robert Hauser, MD, MBA

Person: Principal Investigator, Physician, Director of Clinical Operations
Dr. Hauser is a Professor of Neurology, Molecular Pharmacology, and Physiology at the University Of South Florida Morsani College Of Medicine, in Tampa. He serves as Director of the Clinical Signature Interdisciplinary Program in Neuroscience and as Director of the USF Health Byrd Parkinson's...

Jennifer Koebert, MPAS, MPH, PA-C

Person: Sub-Investigator, Physician Assistant
Jen graduated with a Master’s degree in Physician Assistant Studies from Elon University in 2020, and also earned her Master’s degree in Public Health from the University of Florida in 2014. She has been working with Dr. Hauser at USF as a Physician Assistant since 2020, and previously worked as a...

Erica Botting, BS, CRA-USF/Advanced

Person: Research Site Manager, Office Manager, Senior Clinical Research Associate
Erica Botting is the Research Site Manager and Senior Clinical Research Associate at the prestigious USF Parkinson's Disease and Movement Disorders Center. With a Bachelor of Science in Biology from USF, she returned to her alma mater in 2021 to take on this vital role. Erica boasts an impressive...

Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.

Publication: Journal Article
Hauser, RA, H Barkay, HH Fernandez, J Jimenez-Shahed, SA Factor, N Gross, L Marinelli, et al. 2024. “Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.”. J Clin Psychopharmacol. 2024 Jul-Aug 01;44(4):386-396. Doi: 10.1097/JCP.0000000000001885. Epub 2024 Jun 21.PMID: 38901008.

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment. 2023 Jul 7;9:100212. doi: 10.1016/j.prdoa.2023.100212. eCollection 2023. PMID: 37497384

Publication: Journal Article
Isaacson, SH, RA Hauser, R Pahwa, D Gray, and S Duvvuri. 2023. “Dopamine Agonists in Parkinson’s Disease: Impact of D1-Like or D2-Like Dopamine Receptor Subtype Selectivity and Avenues for Future Treatment. 2023 Jul 7;9:100212. Doi: 10.1016/J.prdoa.2023.100212. ECollection 2023. PMID: 37497384”. Clin Park Relat Disord.

Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson's Disease and Dyskinesia. Neurol Ther. 2021 Dec;10(2):739-751. doi: 10.1007/s40120-021-00256-1.

Publication: Journal Article
Hauser, RA, SH Mehta, D Kremens, D Chernick, and AE Formella. 2021. “Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People With Parkinson’s Disease and Dyskinesia. Neurol Ther. 2021 Dec;10(2):739-751. Doi: 10.1007/S40120-021-00256-1.”. Neurol Ther.

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 2019;18:145-154.

Publication: Journal Article
LeWitt, PA, RA Hauser, R Pahwa, SH Isaacson, HH Fernandez, M Lew, M Saint-Hilaire, et al. 2019. “Safety and Efficacy of CVT-301 (levodopa Inhalation Powder) on Motor Function During off Periods in Patients With Parkinson’s Disease: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. Lancet Neurol 2019;18:145-154.”. Lancet Neurol.